31.38
-1.63%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sinocelltech Group
Its shares trade on Shanghai under the ticker 688520.SS. It has been listed since 22 June 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.56bn and a net loss of CN¥553.3m. At that date it held total assets of CN¥3.82bn and shareholders' equity of CN¥128.3m.
Sinocelltech Group Ltd. engages in the research and development, and manufacture of biopharmaceutical products. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-06-22. The firm focuses on monoclonal antibodies, recombinant proteins and vaccine products. Its main products are SCT800, SCT200, SCT-I10A, SCT400, SCT510, SCT1000 and SCT630, among others. The firm is also engaged in asset leasing business and payment collection business.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Jun 2020
- Employees
- 1,868
- Website
- sinobiological.com ↗
Leadership
Pay as last reported
- Mr. Liangzhi XieChairman of the Board, General Manager, since 2015CN¥171,100
- Ms. Jie MaChief Financial Officer, Director, since 2023CN¥944,700
- Mr. Liming TangDeputy General Manager, Secretary of the Board, Director, since 2016CN¥2.4m
- Mr. Yang WangDeputy General Manager, Director, since 2010CN¥3.4m
- Mr. Zhanghua LanDeputy General Manager, since 2019CN¥2.1m
- Ms. Wenlin GaiDistinguished Clinical Research ExpertCN¥2.6m
- Ms. Chunxia LuoLeader of Pilot Workshop and Production WorkshopCN¥1.5m
- Mr. Fanbin PanHead of Engineering Equipment DepartmentCN¥831,000
- Ms. Chunyun SunExecutive Director of Preclinical R&D CenterCN¥1.4m
- Ms. Yanjing ZhangExecutive Director of Preclinical R&D CenterCN¥1.3m
- Mr. Weiqiang HanDirector
- Ms. Guifen ZhaoDirector, since 2017CN¥456,600
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 50
- Social
- 56
- Governance
- 19
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sinocelltech Group Ltd. employs 1,868 full-time employees in Beijing, China.
- The company's main products include SCT800, SCT200, and SCT-I10A monoclonal antibodies.
- Sinocelltech focuses on biopharmaceutical R&D and manufacturing in the Health Care sector.
Weaknesses
- Sinocelltech Group Ltd. has a limited product portfolio with only seven main products.
- The company's asset leasing business is a minor revenue stream compared to biopharmaceuticals.
- Sinocelltech's IPO in 2020 may indicate limited market capitalization growth potential.
Opportunities
- Sinocelltech can expand its biopharmaceutical product line in the Chinese market.
- Growing demand for monoclonal antibodies in the Health Care industry presents opportunities.
- The company can leverage its Beijing headquarters for strategic partnerships in China.
Threats
- Sinocelltech faces competition from other biotech firms in the Chinese market.
- Regulatory changes in China's biopharmaceutical sector could impact operations.
- The company's reliance on a single market (China) poses a significant risk.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.